Tandem Diabetes Care, Inc. (TNDM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Metabolicsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 20/100 (LOW), 163.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.82% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
- Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks
- Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?
- Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
- Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
- Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
- 5 Must-Read Analyst Questions From Tandem Diabetes’s Q2 Earnings Call
- Tandem Diabetes (TNDM) Q2 2026 Earnings Call Transcript
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial. — Endocrinol Diabetes Metab 2026 Sep PMID 42671087
- Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. — Endocrinol Metab Clin North Am 2026 Sep PMID 42526999
- Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial. — Diabetes Care 2026 Aug 1 PMID 42201836
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tandem Diabetes Care, Inc..
Full TNDM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.